Administration of aldoxorubicin and 14 days continuous infusion of ifosfamide/Mesna in metastatic or locally advanced sarcomas

Fritz C. Eilber MD[1], Kamalesh Kumar Sankhala MD[2], Sant P. Chawla MD[2], Victoria Chua-Alcala[2], Erlinda Maria Gordon MD[2], Doris Quon[2], Katherine Kim[2], Shanta Chawla MD[3], Scott Wieland PhD[3], Daniel J. Levitt MD, PhD[3]

[1]UCLA, Los Angeles, CA; [2]Sarcoma Oncology Center, Santa Monica, CA; [3]CytRx Corporation, Los Angeles, CA

Abstract

Background: Aldoxorubicin (A) has demonstrated superior anti-tumor efficacy and lack of cumulative cardiac toxicity in multiple studies. A is doxorubicin (D) with a linker which rapidly binds in vivo to albumin after iv. We studied the combination of A administered on Day 1 with continuous infusion (CI) of ifosfamide/Mesna (I-M) days 1-14, as first line therapy or second line therapy in patients with sarcomas to evaluate efficacy and toxicity in patients with soft tissue sarcomas (STS) to evaluate efficacy and toxicity. **Methods:** 27 patients have entered the study at 250 mg/m2 (185 mg/m^2 D equiv) administered on Day 1. I-M (1 g/m^2 of each per day) was given up to 14 days as a CI via an out-patient portable pump. Chemotherapy cycles were repeated at 28 day interval. I-M was limited to a maximum of 6 cycles to avoid cumulative marrow toxicity, but A was continued per investigator decision in responding patients or SD patients for clinical benefit. Subjects were followed for tumor response (RECIST 1.1) by CT scans and echocardiogram/ECG for cardiac toxicity every 8 weeks along with standard labs. Enrollment continues up to 50 patients. **Results:** Demographics: 56% M, 44% F; 85% Caucasian, 11% Asian, 4% Black; 67% no prior tx, 26% 1 prior tx, 7%>1 prior tx; Median cum. A=1000 mg/m^2 (740 mg/m^2 D eq.); 185-4070 mg/m^2 D eq.); I=6.9 g/m2 (2.1-12.6 g/m^2). Best response: 42% PR, 58% SD. Median PFS not reached. 10 subjects with either PR or SD had surgery to remove accessible tumors. Range of tumor necrosis=70 to > 95%. Grade 3/4 AEs: neutropenia = 78%, febrile neutropenia = 9%, thrombocytopenia = 22%, anemia = 65%, nausea = 4%. Related SAEs = 4 (febrile neutropenia (2), pyrexia, stomatitis). No tx related deaths. No clinically significant cardiac AEs, no decrease in LVEF > 20%. **Conclusions:** A can be administered for prolonged periods and safely with CI ifosfamide/mesna and achieves high ORR and SD with substantial tumor necrosis.

Background

- Patients with metastatic, locally advanced, or unresectable soft tissue sarcomas have a poor prognosis with progression-free survival of around 4-5 months and median overall survival of approximately 15 months after treatment with single agent doxorubicin.
- Doxorubicin, either alone or in combination with ifosfamide, is still considered the mainstay chemotherapeutic agent for the treatment of advanced, unresectable tumors.
- Aldoxorubicin in combination with a less toxic schedule for administering ifosfamide[1] may improve the activity of this combination without increasing its toxicity as has been demonstrated for ifosfamide as a single agent.
- In a phase 3 trial (EORTC 32012), discontinuation of treatment due to toxicity was 6 times greater in patients treated with doxorubicin and ifosfamide compared to patients receiving single-agent doxorubicin.

Aldoxorubicin

- Aldoxorubicin is a prodrug of the anticancer agent doxorubicin which is derivatized at its C-13 keto-position with a thiol-binding spacer molecule (6-maleimidocaproic acid hydrazide).
- Aldoxorubicin is quantitatively and selectively bound to the cysteine-34 position of endogenous albumin within a few minutes. The reaction follows second-order kinetics.
- Aldoxorubicin was superior to free doxorubicin in several human tumor xenograft models.[2]
- Toxicological studies in mice, rats, and dogs demonstrated a 3- to 5-fold increase in the MTD, moderate and reversible myelosuppression, no liver toxicity and immunotoxicity, and no new toxicity compared to doxorubicin.[3]
- Aldoxorubicin is significantly less cardiotoxic in a chronic rat model when compared to doxorubicin at an equitoxic dose.[4]
- In a first-line STS study, aldoxorubicin significantly increased PFS, PFS at 6 months and ORR compared to doxorubicin.[5]
- Cumulative doses of >10,000 mg/m^2 of doxorubicin equivalents have been achieved, which is over 20 times the peak cumulative dose of standard doxorubicin.
- No clinically significant cardiac toxicities attributed to aldoxorubicin have been observed in clinical trials to date.

Contact Details
Sant P. Chawla, M.D.
Sarcoma Oncology Center
2811 Wilshire Blvd., Suite 414
Santa Monica, CA 90403
(310) 552-9999 – phone
(310) 201-6685 – fax
E-mail schawla@sarcomaoncology.com
www.sarcomaoncology.com

Disclosures
Levitt, Wieland, Chawla, Sung: *CytRx Corporation:* Employment, Equity Ownership.
Chawla, Sankhala, Chawla, Chua-Alcala, Gordon: Research support from *CytRx*
Eilber: No relevant disclosures

Structure of Aldoxorubicin



Objectives

Primary
- To determine the preliminary safety of administration of aldoxorubicin in combination with ifosfamide/Mesna in subjects with metastatic, locally advanced, or unresectable soft tissue sarcoma. Phase 1b part allowed subjects with no prior therapy and phase 2 part allowed subjects either had or had not received prior therapy.

Secondary
- To evaluate the overall response rate, PFS, and PFS at 4 and 6 months.

Study Design

- Aldoxorubicin administered at either 170 or 250 mg/m^2 (125 and 185 mg/m^2 doxorubicin equivalents) intravenously (IV) on Day 1 every 28 days plus 1 gm/m^2/day ifosfamide and equal doses of Mesna by continuous intravenous infusion for up to 10-14 days (based on tolerability) via a portable/ambulatory infusion pump using a central line such as port-a-cath or PICC line.
- A subsequent dose level was to be administered if <2 of 3 or <3 of 6 subjects experienced a dose limiting toxicity during Cycles 1 and 2.
- Subjects with response (CR, PR, or SD) to initial combination therapy may continue with aldoxorubicin alone every 21 days at the same dose as used with the combination until disease progression, unacceptable toxicity or withdrawal of consent.
- The aldoxorubicin 250 mg/m^2 + ifosfamide/mesna dose group is being expanded a second time to further assess the preliminary activity and safety of this combination.
- Tumor response was monitored every 8 weeks using the RECIST 1.1 criteria.
- Safety assessments including adverse events, physical exam, serum chemistry, CBC, urinalysis, and ECG were performed at each visit.
- Cardiac function was assessed using either MUGA or cardiac ultrasound.
- Responses defined using RECIST 1.1 Criteria.

Treatment Schema: 28-Day Cycle



Aldoxorubicin 30 minute I.V. infusion on Day 1

Ifosfamide 1g/m^2/day and Mesna 14-day continuous infusion by portable pump

Key Eligibility Criteria

- Age between 15 and 80 years, male or female.
- Histologically or cytologically confirmed, locally advanced, unresectable, and/or metastatic soft tissue sarcoma (including rhabdomyosarcoma, Ewing's sarcoma and mixed mesodermal sarcoma), chondrosarcoma or osteosarcoma of intermediate or high grade and gastrointestinal stromal tumors (GIST) (only in subjects that have progressed after receiving treatment with imatinib and sunitinib).
- For subjects without prior therapy, adjuvant or neoadjuvant chemotherapy (including doxorubicin) is allowed if no tumor recurrence for at least 12 months since the last measurement, beginning or end of last chemotherapy.
- For subjects with prior therapy, no more than 2 prior regimens, and no prior exposure to ifosfamide and up to 375 mg/m^2 prior doxorubicin.
- ECOG performance status 0-2.
- Life expectancy >12 weeks.

Patient Characteristics*

Characteristics	170 mg/m^2	250 mg/m^2
N	7	38
Median Age, y (range)	42 (21-63)	55 (18-75)
Male / Female, # (%)	5 (71) / 2 (29)	23 (61) / 15 (39)
Race, # (%)		
Caucasian	6 (86)	33 (87)
Black or African American	1 (14)	1 (3)
Asian	0 (0)	4 (11)
American Indian or Alaska native	0 (0)	0 (0)
ECOG, # (%)		
0	0 (0)	0 (0)
1	7 (100)	38 (100)
First-line Therapy # (%)	7 (100)	25 (66)
Prior Chemotherapy (≥ 1), # (%)	0 (0)	13 (34)
Completed Aldoxorubicin Cycles, median (range)	5 (2-21)	6 (1-28)**
Completed Ifosfamide Cycles#, median (range)	5 (2-6)	4 (1-6)**
Cumulative Aldox Dose (mg), median (range)	1836 (748-7146)	2645 (350-10500)
Cumulative Dox equivalents (mg), median (range)	1364 (556-5309)	1965 (260-7800)

*as of 10May2017; #6 cycles were the maximum allowed; **several subjects just started the study

Results

Best Response	170 mg/m^2 (%) N=7	250 mg/m^2 (%)+ N=37
Complete Response	0 (0)	0 (0)
Partial Response	2 (29)	14 (38)
Stable Disease	4 (57)	21 (57)
Progressive Disease	1 (14)	0 (0)
Not Determined	0 (0)	2 (5)
Disease Control Rate++ (%)	2 (29)	18 (49%)

+37 subjects have had a scan post-treatment as of 10May2017. ++DCR: ORR+SD>4 months

Waterfall Plot – Target Lesion Change



Representative CT Scans



73% Tumor reduction following 2 cycles of aldoxorubicin + ifosfamide (Subject 01-060)



Significant calcification and over 20% of tumor reduction following 14 cycles of aldoxorubicin + 6 cycles ifosfamide/Mesna (Subject 01-028)

Cardiac Evaluation

- No clinically significant cardiotoxicity has been observed.
- No patients had clinically significant decrease in LVEF or QTc prolongation.

Other Significant Findings

- Among the patients who proceeded with post-treatment surgery (N=10), half of the patients had tumor necrosis of 90% or more, and nine out of ten subjects had tumor necrosis of 70% or above.
- No alopecia observed with aldoxorubicin.

No hair loss following 20 cycles of aldoxorubicin, who initially developed alopecia during the first 6 cycles of Ifosfamide/Mesna (Subject 01-013)

Grade 3/4 Treatment Emergent Adverse Events (related to either or both)

	170 mg/m^2		250 mg/m^2	
	No. (%)		No. (%)	
Event	**Gr. 3**	**Gr. 4**	**Gr. 3**	**Gr. 4**
Neutropenia	1 (14)	5 (71)	7 (18)	16 (42)
Anemia	4 (57)		18 (47)	3 (8)
Thrombocytopenia			4 (11)	3 (8)
Febrile neutropenia		1 (14)	2 (5)	4 (11)
Leucopenia			2 (5)	1 (3)
Nausea/Vomiting			2 (5)	
Mucositis			1 (3)	
Decreased WBC			1 (3)	

As of 10May2017 data available; N=7 (170 mg/m^2); N=38 (250 mg/m^2)

Serious Adverse Events (related to either or both)

- SAEs included febrile neutropenia (6), thrombocytopenia (1), stomatitis (1), pyrexia (1) and anemia (2).
- No treatment-related deaths occurred.

Conclusions

- Aldoxorubicin can be administered safely with continuous infusion of ifosfamide/Mesna.
- No DLTs were observed in either cohort.
- Treatment was associated with a HIGH percentage of objective responses or stable disease.
- Common Grade 3 and 4 AEs (>20%) were neutropenia and anemia. BUT NOT FEBRILE NEUTROPENIA.
- The median cumulative dose of aldoxorubicin for the 170 mg/m^2 cohort is 1836 mg/m^2 (range: 748-7146) (doxorubicin equivalents 1364 mg/m^2 [range: 556-5309]).
- The median cumulative dose of aldoxorubicin for the 250 mg/m^2 cohort is 2645 mg/m^2 (range: 350-10500) (doxorubicin equivalents 1965 mg/m^2 [range: 260-7800]).
- No clinically significant cardiac problems were observed despite administration of median cumulative dose of doxorubicin equivalents of 1364-1965 mg/m^2.
- Based on experience gained in this study, the decision was made to stop further aldoxorubicin dose escalation and continue to enroll the 250 mg/m^2 cohort. mPFS has not been reached at this time.

References

1. Singh AS, Sankhala K, Mukherjee A, et al. 14 Day continuous infusion ifosfamide in advanced refractory sarcomas. *Sarcoma Res Int.* 2015;2(1):1010.
2. Kratz F, Beyer U. Serum proteins as drug carriers of anticancer agents: a review. *Drug Delivery*. 1998;5:281-299.
3. Kratz F, Ehling G, Kauffman H. Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin. *Human Exp. Toxicol.* 2007;19-35.
4. Lebrecht D, Geist A, Ketelsen U, et al. The 6-maleimidocaproyl hydrazone derivative of doxorubicin (DOXO-EMCH) is superior to free doxorubicin with respect to cardiotoxicity and mitochondrial damage. *Int J Cancer*. 2007;120:927-934.
5. Chawla S, Papai Z, et al. First-line aldoxorubicin vs doxorubicin in metastatic or locally advanced unresectable soft-tissue sarcoma. *JAMA Oncol.* 2015Sept17;1-9.